Crystalline Trilaciclib Citrate Salt for Stable Drug Formulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for additional solid state forms of Trilaciclib and its salts to improve formulation, processing, stability, and bioavailability, particularly for treating chemotherapy-induced bone marrow suppression in various cancers.
Innovation Solution
The development of crystalline Trilaciclib citrate salt and its pharmaceutical compositions, which can be used to prepare other forms of Trilaciclib or its salts, and are suitable for reducing chemotherapy-induced bone marrow suppression in patients with specific types of cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If new solid state forms of Trilaciclib and its salts are developed, then stability, handling, and dissolution profiles are improved, but formulation complexity increases
Solution Approach 1:
The patent applies parameter changes by developing different solid state forms (polymorphs, salts, solvates) of Trilaciclib, each with distinct physical and chemical parameters. For example, the Trilaciclib citrate salt form exhibits improved stability and dissolution profiles compared to other forms, while Form I and Form II polymorphs offer different handling characteristics. This systematic variation of physical parameters enables optimization of formulation properties without fundamentally changing the molecular structure.
Solution Approach 2:
The patent employs composite materials by creating salt forms of Trilaciclib with different counterions (citrate, dihydrochloride, hydrochloride, sulfate, mesylate, besylate, trifluoroacetate). Each salt form combines Trilaciclib with a specific counterion to achieve desired properties such as enhanced stability, improved solubility, or better processing characteristics. The Trilaciclib citrate salt represents a composite material that optimizes multiple properties simultaneously.
2Ease of manufacture
If different salts and solid state forms are used, then processing and handling characteristics are improved, but manufacturing complexity increases
Solution Approach 1:
The patent utilizes parameter changes by establishing specific crystallization conditions for each Trilaciclib salt form and polymorph. For instance, Form I and Form II can be obtained through controlled crystallization from different solvent systems, and the Trilaciclib citrate salt exhibits superior processing characteristics when prepared under optimized conditions. By systematically varying crystallization parameters (solvent type, temperature, pH), the patent enables selective production of forms with desired handling properties.
Solution Approach 2:
The patent applies preliminary action by pre-establishing the optimal preparation methods for each Trilaciclib salt form and polymorph before actual manufacturing. The detailed characterization data (XRD patterns, DSC thermograms, solubility profiles) provided for each form serves as a reference guide for manufacturing, enabling consistent reproduction of the desired solid state form without requiring complex real-time adjustments during production.
3Ease of operation
If additional solid state forms are discovered, then bioavailability and dissolution profile are improved, but purification difficulty increases
Solution Approach 1:
The patent applies parameter changes by exploiting the distinct solubility characteristics of different Trilaciclib solid state forms to achieve purification. The Trilaciclib citrate salt and various polymorphs exhibit different solubility profiles in common pharmaceutical solvents, enabling selective dissolution and recrystallization procedures. This allows purification of the desired form while maintaining its specific dissolution properties, as the purification process itself leverages the unique parameters of each form rather than requiring complex separation techniques.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present disclosure encompasses solid state forms of Trilaciclib and of Trilaciclib salts, in embodiments crystalline polymorphs of Trilaciclib and of Trilaciclib salts, processes for preparation thereof, and pharmaceutical compositions thereof.